

Colin Reisner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8070232/publications.pdf>

Version: 2024-02-01

25
papers

668
citations

759055

12
h-index

580701

25
g-index

25
all docs

25
docs citations

25
times ranked

538
citing authors

#	ARTICLE	IF	CITATIONS
1	A randomized controlled trial of glycopyrrolate administered by metered dose inhaler in patients with uncontrolled asthma despite ICS/LABA treatment. <i>Journal of Asthma</i> , 2022, 59, 1420-1432.	0.9	2
2	Efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler delivered using co-suspension delivery technology in Japanese patients with moderate-to-very severe chronic obstructive pulmonary disease. <i>Respiratory Investigation</i> , 2021, 59, 135-144.	0.9	1
3	Functional respiratory imaging assessment of glycopyrrolate and formoterol fumarate metered dose inhalers formulated using co-suspension delivery technology in patients with COPD. <i>Therapeutic Advances in Respiratory Disease</i> , 2020, 14, 175346662091699.	1.0	5
4	Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies. <i>Respiratory Research</i> , 2020, 21, 128.	1.4	4
5	<p>Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 43-56.	0.9	7
6	<p>Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 99-106.	0.9	3
7	<p>Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 2993-3002.	0.9	12
8	<p>Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS Study</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 2979-2991.	0.9	12
9	Randomized study of the effects of Aerochamber Plus Â® Flow-Vu Â® on the efficacy, pharmacokinetics and safety of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler in patients with chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2018, 138, 74-80.	1.3	11
10	Randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of three doses of co-suspension delivery technology glycopyrronium MDI in Japanese patients with moderate-to-severe COPD. <i>International Journal of COPD</i> , 2018, Volume 13, 1187-1194.	0.9	8
11	A randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPD. <i>International Journal of COPD</i> , 2018, Volume 13, 2673-2684.	0.9	21
12	Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA. <i>International Journal of COPD</i> , 2018, Volume 13, 2969-2984.	0.9	34
13	Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2018, 6, 747-758.	5.2	254
14	Pharmacokinetics and safety of a single dose of the novel LAMA/LABA fixed-dose combination of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler, formulated using co-suspension delivery technology, in Japanese healthy subjects. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 53, 33-38.	1.1	8
15	Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD. <i>International Journal of COPD</i> , 2018, Volume 13, 1483-1494.	0.9	4
16	Safety and pharmacokinetics of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) in healthy adult subjects of Japanese descent. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 51, 18-25.	1.1	6
17	Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD. <i>International Journal of COPD</i> , 2018, Volume 13, 1965-1977.	0.9	4
18	Pharmacokinetics of glycopyrronium/formoterol
fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD. <i>International Journal of COPD</i> , 2018, Volume 13, 945-953.	0.9	14

#	ARTICLE	IF	CITATIONS
19	A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension [®] , [®] Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2017, 18, 8.	1.4	21
20	Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD. <i>Chest</i> , 2017, 151, 340-357.	0.4	91
21	Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension [®] , [®] Delivery Technology in patients with chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2017, 126, 105-115.	1.3	63
22	Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered Dose Inhaler in COPD. <i>Chest</i> , 2017, 152, 1169-1178.	0.4	34
23	24-h bronchodilation and inspiratory capacity improvements with glycopyrrolate/formoterol fumarate via co-suspension delivery technology in COPD. <i>Respiratory Research</i> , 2017, 18, 157.	1.4	15
24	Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension [®] , [®] Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD. <i>Respiratory Research</i> , 2016, 17, 109.	1.4	16
25	A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD. <i>Respiratory Medicine</i> , 2016, 120, 16-24.	1.3	18